Jeff Szer
About
In The Last Decade
Jeff Szer
371 papers receiving 15.0k citations
Hit Papers
Peers
Comparison fields: 5 of 161
- Hematology 8.4k
- Immunology 4.8k
- Oncology 3.5k
- Genetics 3.2k
- Public Health, Environmental and Occupational Health 1.9k
Countries citing papers authored by Jeff Szer
This map shows the geographic impact of Jeff Szer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Szer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Szer more than expected).
Fields of papers citing papers by Jeff Szer
This network shows the impact of papers produced by Jeff Szer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Szer. The network helps show where Jeff Szer may publish in the future.
Co-authorship network of co-authors of Jeff Szer
This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Szer. A scholar is included among the top collaborators of Jeff Szer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Szer. Jeff Szer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 19 | |
| 5 | 7 | |
| 6 | 2 | |
| 7 | 5 | |
| 8 | 6 | |
| 9 | 5 | |
| 10 | 43 | |
| 11 | 3 | |
| 12 | 2 | |
| 13 | Long-term effects in subgroups of patients with paroxysmal nocturnal hemoglobinuria treated with pegcetacoplan versus eculizumab: 48-week analysis of pegasus phase 3 trial | 1 |
| 14 | 13 | |
| 15 | 11 | |
| 16 | 1 | |
| 17 | A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase | 1 |
| 18 | 16 | |
| 19 | Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: Efficacy and concomitant cyclosporin A (Mycoses (2007) 50, SUPPL. 1, (24-37)) | 2 |
| 20 | Combination prophylactic immunosuppression in bone marrow transplantation. | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.